Broad-Spectrum Antiviral Strategies and Nucleoside Analogues
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast response is essential to face an outbreak crisis as well as for bioweapon countermeasures. So far, broad-spectrum antivirals include two main categories: the family of drugs targeting the host-cell machinery essential for virus infection and replication, and the family of drugs directly targeting viruses. Among the molecules directly targeting viruses, nucleoside analogues form an essential class of broad-spectrum antiviral drugs. In this review, we will discuss the interest for broad-spectrum antiviral strategies and their limitations, with an emphasis on virus-targeted, broad-spectrum, antiviral nucleoside analogues and their mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
First report of autochthonous transmission of Zika virus in Brazil
Zanluca, C., Melo, V. C. A. D., Mosimann, A. L. P., Santos, G. I. V. D., Santos, C. N. D. D., & Luz, K. (2015) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760150192 · Cited by 1,320 · cited 1×
“The time constraint for antiviral drug discovery has gradually become more important due to the increasing number of viral outbreaks that have recently and consecutively afflicted our societies including Ebola virus [3], Middle East Respiratory Syndrome coronavirus MERS-CoV [4], Severe Acute Respiratory Syndrome Coron…”
BackgroundStructural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
Mutation rates among RNA viruses
Drake, J. W., & Holland, J. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13910 · Cited by 1,143 · cited 1×
“Most RNA viruses possess a high mutation rate that allows them to adapt, escape host immune defenses and drug treatments [71,72].”
BackgroundLack of evidence for proofreading mechanisms associated with an RNA virus polymerase
Steinhauer, D. A., Domingo, E., & Holland, J. J. (1992) · Gene · doi:10.1016/0378-1119(92)90216-c · Cited by 415 · cited 1×
“The high error-prone nature of viral RdRps is widely recognized as the main source for the virus high mutation rate [73,74].”
BackgroundDrugs, Devices, and the FDA: Part 1
Van Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.002 · Cited by 366
Cited by
(2026) · doi:10.1021/acs.biochem.6c00271 · Cited by 1
Metadata
- Authors
- Geraghty, R., Aliota, M., & Bonnac, L.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2021-04-13
- Volume
- 13
- Issue
- 4
- Pages
- 667
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W3152728485
- Cited by
- 208
- References
- 7
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. https://app.cochat.ai/papers/10.3390/v13040667
- The paper
- Geraghty, R., Aliota, M., & Bonnac, L. (2021). Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses. https://doi.org/10.3390/v13040667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.